title: Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B.
abstract: Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis. Optimal dose is not defined. We described a case of pulmonary mucormycosis, which had been treated with 42.55 g (during to 45 weeks) liposomal amphotericin B. In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.
authors.affiliation: Division of Pediatric Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey. erbeyfa@gmail.com
authors.forename: Fatih
authors.initials: F
authors.lastname: Erbey
authors.forename: Emine
authors.initials: E
authors.lastname: Kocabaş
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Bayram
authors.forename: Süreyya
authors.initials: S
authors.lastname: Soyupak
authors.forename: Derya
authors.initials: D
authors.lastname: Gümürdülü
authors.forename: Atila
authors.initials: A
authors.lastname: Tanyeli
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009091:Mucormycosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B